Hanmi Pharm. Co., Ltd.

Myongji University Industry and Academia Cooperation Foundation

Myongji University Industry and Academia Coop Fdn

Jung Kuk Kim

Sung Youb Jung

In Young Choi

Young Jin Park

Se Chang Kwon

Dae Jin Kim

Jae Hyun Park

Jong Min Lee

Min Kyu Kim

Sung Min Bae

Sang Yun Kim

Jong Suk Lee

Yong Ho Heo

Hyo Sang Jo

Hyun Joo Kwon

Eun Jin Park

A vibration detection apparatus is disclosed. The vibration detection apparatus comprises a body configured to have internal space, and a vibration sensor formed on the body and configured to sense vibration from a measuring object. Here, a space exists between the vibration sensor and a surface opposed to the vibration sensor of the body.

Vibration detection apparatus

A glucagon derivative, a long-acting conjugate of the glucagon derivative, and a use thereof are disclosed.

Glucagon derivative and a composition comprising a long acting conjugate of the same

The present invention relates to a glucagon derivative, a conjugate thereof, and a composition comprising the same, and a therapeutic use thereof, and in particular, for metabolic syndrome, hypoglycemia, and congenital hyperinsulinism.

Glucagon derivative, conjugate thereof, composition comprising same, and therapeutic use thereof

The present invention relates to a novel glucagon derivative peptide, and a composition for preventing or treating hypoglycemia containing the novel glucagon derivative peptide as an active ingredient. The glucagon derivative according to the present invention has improved physical properties due to the change in isoelectric point (pI) while being capable of maintaining an activity on glucagon receptors, and thus can improve patient compliance when used as a hypoglycemic agent, and is also suitable for administration in combination with other anti-obesity agents. Accordingly, the glucagon derivative according to the present invention can be effectively used for the prevention and treatment of hypoglycemia and obesity.

Glucagon derivatives with improved stability

A facial skin care device and a method of operating the same are disclosed. The facial skin care device comprises an oral insertion module configured to have a structure inserted in an oral cavity and include one or more oral electrodes contacted with a skin in the oral cavity, and a main body configured to include a main electrode connected electrically to at least one of the oral electrode on an outer surface of a facial skin and a current generation unit which is connected to the main electrode and generates current for applying electrical stimulation to the facial skin.

Facial skin care device and operation method therefor

The present invention relates to a conjugate in which an immunoglobulin Fc region is linked to therapeutic enzymes through a non-peptide polymer linkage moiety, and more specifically, to a conjugate in which a non-peptide polymer linkage moiety is specifically linked to an immunoglobulin Fc, a method of preparing the same, and a composition comprising the same.

Conjugate of therapeutic enzymes

The present invention relates to a glucagon derivative, a long-acting conjugate of the glucagon derivative, and a use thereof.

The present invention relates to a composition for the prevention or treatment of diabetes including a long-acting insulin conjugate and a long-acting insulinotropic peptide conjugate, and a method for treating diabetes. More specifically, combination administration of the long-acting analog conjugate and the long-acting insulinotropic peptide conjugate inhibits weight gain due to administration of insulin, and vomiting and nausea due to administration of the insulinotropic peptide, and also reduces the required doses of insulin, thereby remarkably improving drug compliance. In addition, the present invention relates to administering a pharmaceutical composition for reducing side effects of pancreatic beta cells in diabetic patients, including a long-acting insulin analog conjugate and a long-acting insulinotropic peptide analog conjugate, and to a method for reducing side effects of pancreatic beta cells in diabetic patients, including the step of administering the composition. Specifically, the present invention is characterized in reducing side effects such as abnormality in the function of pancreatic beta cells associated with the development of diabetes, reduction in the pancreatic beta cell mass, lipotoxicity, or glucotoxicity.

Growing community of inventors

Hwaseong-si, South Korea

Jung Kuk Kim